X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1234) 1234
complement (709) 709
eculizumab (559) 559
female (468) 468
male (436) 436
animals (358) 358
immunology (350) 350
hematology (343) 343
complement activation (338) 338
complement inhibitor eculizumab (319) 319
hemolytic-uremic syndrome (317) 317
antibodies, monoclonal, humanized - therapeutic use (312) 312
adult (304) 304
urology & nephrology (292) 292
transplantation (268) 268
activation (253) 253
thrombotic microangiopathy (215) 215
middle aged (214) 214
atypical hemolytic uremic syndrome (192) 192
paroxysmal-nocturnal hemoglobinuria (192) 192
alternative pathway (187) 187
care and treatment (184) 184
treatment outcome (183) 183
medicine & public health (180) 180
mutation (177) 177
diagnosis (176) 176
inflammation (176) 176
proteins (173) 173
disease (172) 172
research (152) 152
paroxysmal nocturnal hemoglobinuria (150) 150
kidney transplantation (148) 148
complement system proteins - immunology (147) 147
adolescent (145) 145
thrombosis (145) 145
mice (142) 142
pediatrics (142) 142
analysis (141) 141
child (140) 140
nephrology (139) 139
antibodies (137) 137
monoclonal antibodies (134) 134
aged (133) 133
young adult (133) 133
health aspects (131) 131
hemolytic uremic syndrome (131) 131
review (131) 131
kidneys (129) 129
risk factors (126) 126
complement inactivating agents - therapeutic use (123) 123
patients (122) 122
hemolysis (115) 115
mutations (115) 115
therapy (115) 115
abridged index medicus (114) 114
medicine, general & internal (114) 114
hemoglobinuria, paroxysmal - drug therapy (112) 112
anemia (110) 110
thrombotic thrombocytopenic purpura (110) 110
complement system proteins - metabolism (109) 109
surgery (109) 109
antibodies, monoclonal - therapeutic use (108) 108
complement activation - drug effects (104) 104
complement c5 - antagonists & inhibitors (103) 103
glomerulonephritis (101) 101
pathogenesis (100) 100
factor-h (99) 99
pregnancy (98) 98
complement activation - immunology (96) 96
natural-history (96) 96
complement system (95) 95
hemic and lymphatic diseases (94) 94
membranoproliferative glomerulonephritis (94) 94
membrane attack complex (93) 93
medicine (92) 92
disease models, animal (91) 91
dense deposit disease (90) 90
antibody-mediated rejection (89) 89
inhibitor eculizumab (88) 88
oncology (88) 88
recurrence (87) 87
antibodies, monoclonal, humanized (86) 86
biopsy (86) 86
children (86) 86
macular degeneration (86) 86
medicine, research & experimental (86) 86
ahus (85) 85
management (85) 85
pathology (85) 85
plasma exchange (84) 84
autoantibodies (82) 82
complement factor h - genetics (82) 82
kidney diseases (81) 81
transplants & implants (80) 80
internal medicine (79) 79
physiological aspects (79) 79
complement component c3 (78) 78
immunoglobulins (78) 78
decay-accelerating factor (77) 77
prognosis (77) 77
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1765) 1765
German (25) 25
French (9) 9
Spanish (9) 9
Japanese (3) 3
Italian (1) 1
Korean (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2013, Volume 368, Issue 23, pp. 2169 - 2181
Journal Article
Nature Reviews Drug Discovery, ISSN 1474-1776, 07/2007, Volume 6, Issue 7, pp. 515 - 516
  Eculizumab (Soliris; Alexion), a monoclonal antibody that binds to the terminal complement protein C5, was approved by the FDA for the treatment of patients with paroxysmal nocturnal haemoglobinuria in March 2007... 
PHARMACOLOGY & PHARMACY | PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | COMPLEMENT INHIBITOR ECULIZUMAB | HEMOLYSIS | Antibodies, Monoclonal, Humanized | Antibodies, Monoclonal - therapeutic use | Humans | Hemoglobinuria, Paroxysmal - drug therapy | Monoclonal antibodies | Complications and side effects | Dosage and administration | Blood diseases | Drug therapy
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1377 - 1380
.... In trial 1, a shorter delay before administration of the first dose of eculizumab was reported to result in a better recovery of renal function... 
EQ-5D | MEDICINE, GENERAL & INTERNAL | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Female | Male | Thrombotic Microangiopathies - prevention & control | Complement C5 - antagonists & inhibitors | Hemolytic-Uremic Syndrome - drug therapy | Renal function
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 381, Issue 7, pp. 614 - 625
Journal Article
Journal Article
Journal Article
Journal Article
Blood, ISSN 1528-0020, 2017, Volume 130, Issue 3, pp. 368 - 372
Publisher's Note: There is an Inside Blood Commentary on this article in this issue. 
GENE-MUTATIONS | RARE DISEASES | HEMATOLOGY | COMPLEMENT INHIBITOR ECULIZUMAB | DISCONTINUATION | Letter to
Journal Article
Journal Article
Journal Article